Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System
CHEST JournalPublished 1 January 2003
David E. Geller, Margaret Rosenfeld, David A. Waltz, Robert W. Wilmott
Citations80
SJR quartileQ1
SJR score1.83
SNIP1.83
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Compared with the standard nebulizer, the AeroDose safely achieved an approximately threefold greater efficiency in the delivery of TSI to the lungs in less than half the time.
Abstract
Compared with the standard nebulizer, the AeroDose safely achieved an approximately threefold greater efficiency in the delivery of TSI to the lungs in less than half the time.
Keywords
Medicine
American Review of Respiratory DiseaseStandardization of Spirometry — 1987 Update
3,276 Citations1987A. Sonia Buist
PubMedChanges in the normal maximal expiratory flow-volume curve with growth and aging.
1,917 Citations1983Ronald J. Knudson, M D Lebowitz +2 more
Improved prediction equations for each sex by age group for 5 spirometric and flow-volume variables are derived and "Normal" limits are proposed that take into consideration the between-subject variability and non-Gaussian distribution of the various measurements.
New England Journal of MedicineIntermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
1,292 Citations1999Bonnie W. Ramsey, Margaret S. Pepe +10 more
In a 24-week study of patients with cystic fibrosis, intermittent administration of inhaled tobramycin was well tolerated and improved pulmonary function, decreased the density of P. aeruginosa in sputum, and decreased the risk of hospitalization.
The Journal of PediatricsThe diagnosis of cystic fibrosis: A consensus statement
1,077 Citations1998Beryl J. Rosenstein, Garry R. Cutting
Clinical judgment will continue to be essential in patients who have typical or "atypical" clinical features but who lack conclusive evidence of CFTR dysfunction, and such patients will require close clinical follow-up along with laboratory reevaluation as appropriate.
New England Journal of MedicineEfficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
455 Citations1993Bonnie W. Ramsey, Henry L. Dorkin +10 more
The short-term aerosol administration of a high dose of tobramycin in patients with clinically stable cystic fibrosis is an efficacious and safe treatment for endobronchial infection with P. aeruginosa.
New England Journal of MedicineThe Diagnosis of Cystic Fibrosis
323 Citations1997Robert C. Stern
The primary manifestations of cystic fibrosis are presumably related, at least in part, to abnormal transport of electrolytes, and the .
CHEST JournalPharmacokinetics and Bioavailability of Aerosolized Tobramycin in Cystic Fibrosis
301 Citations2002David E. Geller, William H. Pitlick +3 more
High sputum concentrations ensure efficacious antibiotic levels at the site of the infection and significantly improved the therapeutic ratio over that of parenteral aminoglycosides in cystic fibrosis patients during the pivotal phase III trials.
American Review of Respiratory DiseaseQuantitative Deposition of Aerosolized Gentamicin in Cystic Fibrosis
249 Citations1987Jonathan Ilowite, Jack D. Gorvoy +1 more
Standardizing an aerosol system for delivery of antibiotics and other agents to patients with CF tests the importance of type of nebulizer, droplet size, and dose to the lung in assessing the results of aerosol therapy and finds a bell-shaped relationship between deposited dose and minute ventilation.
PubMedAminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.
218 Citations1985Paul M. Mendelman, Arnold L. Smith +4 more
It is concluded that tobramycin penetrates cystic fibrosis sputum and accumulates over time and 3 wk of intravenous therapy combined with an antipseudomonal beta-lactam antibiotic may be effective in eradication of P. aeruginosa fromSputum of certain CF patients.
Clinical ChemistryFluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma.
164 Citations1981Michael E. Jolley, Stephen D. Stroupe +5 more
Fluorescence polarization immunoassays of the aminoglycoside antibiotics gentamicin, tobramycin, and amikacin in plasma and serum are described and shown to be clinically useful.
Pediatric PulmonologySafety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
142 Citations1989Arnold L. Smith, Bonnie W. Ramsey +6 more
It is concluded that thrice daily aerosol tobramycin administration for 3 months is not associated with detectable eighth cranial nerve or renal toxicity, and transient emergence of tobramYcin resistant P. aeruginosa may occur.
European Respiratory JournalInhalation of antibiotics in cystic fibrosis
140 Citations1995Daan J. Touw, RW Brimicombe +3 more
Aerosol maintenance treatment with an appropriate antibiotic in high enough dosage can be recommended for patients with cystic fibrosis chronically infected with P. aeruginosa, and may improve lung function and reduce the number of hospital admissions due to an acute exacerbation.
DrugsDrug-induced Ototoxicity
135 Citations1980Robert E. Brummett
In laboratory animals it has been clearly demonstrated that excessively loud noise, and concurrent administration of aminoglycoside antibiotics, results in augmented ototoxicity.
CHEST JournalA Comparison of Peak Sputum Tobramycin Concentration in Patients With Cystic Fibrosis Using Jet and Ultrasonic Nebulizer Systems
114 Citations1997Jay D. Eisenberg, Margaret S. Pepe +5 more
Whether adequate concentrations of a new formulation of tobramycin could be delivered to the lower respiratory tract of patients with cystic fibrosis using a jet nebulizer delivery system using a multicenter, open-label, randomized, crossover study is studied.
Respiratory MedicineThe quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis
106 Citations1994Somnath Mukhopadhyay, G.E. Staddon +4 more
The proportion of tobramycin reaching the lungs was small and variable, and the mean penetration index increased with increase in the FRC, but bore no relation to other respiratory function tests or to chest X-ray scores.
The Journal of Infectious DiseasesBioactivity of Gentamicin in Purulent Sputum from Patients with Cystic Fibrosis or Bronchiectasis: Comparison with Activity in Serum
100 Citations1983J Lévy, Arnold L. Smith +3 more
Purulent sputum, whether from children with cystic fibrosis or adults which bronchiectasis, is more inhibitory than serum; the greater degree of binding, rather than differences in the composition or quantity of cations, explains this difference.
Pediatric PulmonologyEfficacy and safety of aerosolized tobramycin in cystic fibrosis
85 Citations2001Vinita B. Pai, Milap C. Nahata
Tobramycin, nebulized at 600 mg three times daily, significantly improved clinical and pulmonary functions and reduced the density of Pseudomonas aeruginosa in the sputum.
American Journal of Respiratory and Critical Care MedicineRhDNase I Aerosol Deposition and Related Factors in Cystic Fibrosis
84 Citations1997P. Diot, Lucy B. Palmer +4 more
The deposition pattern of rhDNase I aerosols in patients with CF is largely influenced by respiratory physiology, which itself depends upon age and severity of lung disease.
Otolaryngologic Clinics of North AmericaGuide for the Evaluation of Hearing Handicap
69 Citations1979Francis I. Catlin
Clinical Infectious DiseasesComparative Studies of Intermittent and Continuous Administration of Aminoglycosides in the Treatment of Bronchopulmonary Infections Due to Gram-Negative Bacteria
44 Citations1981Jean Klášterský, J.P. Thys +1 more
American Review of Respiratory DiseasePulmonary Disposition of Tobramycin
43 Citations1983A.C. Braude, Adriana Hornstein +3 more
It is concluded that the disposition of tobramycin in bronchial secretions and BAL fluid differ, and sampling both fluids offers a more suitable method to study antibiotic pharmacokinetics in bronchi and alveoli.
Pediatric PulmonologyNebulizer delivery of tobramycin to the lower respiratory tract
26 Citations1994Allan Weber, Arnold L. Smith +3 more
The Ultra Neb 100 consistently delivered tobramycin to the lower respiratory tract in patients with CF, and no statistically significant difference was found when using either compressed air, helox, or ambient air.
Respiratory MedicineConcentration of tobramycin given by aerosol in the fluid obtained by bronchoalveolar lavage
24 Citations1990Dana Baran, Paul De Vuyst +1 more
Bronchoalveolar fluid was analysed for tobramycin levels after aerosolization of this antibiotic to help explain why aerosol antibiotic treatment appears to be useful in selected patients, especially in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa.
PubMedBronchial secretion concentrations of tobramycin.
20 Citations1982Michael R. Alexander, J Schoell +3 more
The mean concentrations of tobramycin in bronchial secretions from patients with pneumonia were almost two times greater than secretion from patients free of lung infection, suggesting that lung infection enhances the concentrations of TobramYcin in Bronchial Secretions.
American Journal of TherapeuticsTOBRAMYCIN SERUM CONCENTRATIONS AFTER AEROSOL AND ORAL ADMINISTRATION IN CYSTIC FIBROSIS
17 Citations1995Allan Weber, Judy Williams‐Warren +2 more
Tobramycin has poor systemic absorption in CF subjects after aerosol administration, in part due to the gastrointestinal absorption of swallowed drug, as well as absorption from lower respiratory tract.
Current Opinion in Pulmonary MedicineChoosing a nebulizer for cystic fibrosis applications
11 Citations1997David E. Geller
Breath-enhanced (Venturi) jet neBulizers are less wasteful than constant-output nebulizers and perform better than conventional nebulizer with many drugs, and improved technologies will evolve to target therapies to the lung.
Archives of Disease in ChildhoodImprovement of nebulised antibiotic delivery in cystic fibrosis
11 Citations1999David J. Wilson, Maria Burniston +5 more
A smaller particle size results in a more homogenous distribution of the antibiotic in the lungs with decreased stomach deposition and should not be seen as a recommendation to use the Optimist nebuliser.
Clinical Pulmonary MedicineAerosolized Antibiotics for Bacterial Lower Airway Infections
7 Citations1997Margaret Rosenfeld, Morty Cohen +2 more
Postgraduate Medical JournalAntibiotics in Cystic Fibrosis
3 Citations1964Arne Norman
In cystic fibrosis the main problem is the susceptibility of the children to respiratory infection, but the maxillary antra usually contain muco-pus from the early years.
Journal of Aerosol MedicineDrug Uptake in the Trachea
2 Citations1996J. G. Widdicombe
The most likely explanation of this apparently paradoxical result is that increases in vascular pressure and flow result in a greater interstitial liquid volume and thus perfusion barrier, and induce solvent drag across the vascular endothelial wall, which will limit uptake of agents into the vascular lumen.